{"id":"W4406124968","doi":"10.1177/17588359241308784","title":"The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; William Osler Health System; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Dalhousie University; University of Toronto; University of Manitoba; Juravinski Cancer Centre; University of British Columbia; University Health Network; Ottawa Hospital; CancerCare Manitoba; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Eli Lilly Canada; Bayer Canada; Pfizer Canada; Novartis Pharmaceuticals Canada; Bristol-Myers Squibb Canada; EMD Serono; Astellas Pharma; Genentech; AstraZeneca Canada; Amgen Canada; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Epidermal growth factor receptor; KRAS; Anaplastic lymphoma kinase; Medicine; Crizotinib; Cancer research; Lung cancer; ROS1; Erlotinib; Clinical trial; Biomarker; EGFR inhibitors; Cancer; Targeted therapy; Oncology; Internal medicine; Biology; Adenocarcinoma; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005798019,0.0003863867,0.002073192,0.002655942,0.0002062151,0.001926163,0.0006387554,0.0007663267,0.002275538],"category_scores_gemma":[0.007205553,0.0001745272,0.0008534555,0.002981383,0.0005205984,0.002738603,0.0005864411,0.001215361,0.000614426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009124533,"about_ca_system_score_gemma":0.002165401,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003095312,"about_ca_topic_score_gemma":0.001096602,"domain_scores_codex":[0.9974114,0.001198006,0.0005642927,0.0001921741,0.0005567529,0.00007731035],"domain_scores_gemma":[0.9903026,0.007430528,0.0009326327,0.0001757458,0.001013819,0.0001446397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003380138,0.0001025539,0.0009601245,0.03884003,0.0002798741,0.0002897024,0.0001387012,0.0007411047,0.003823905,0.004766481,0.00695179,0.9427677],"study_design_scores_gemma":[0.0002154863,0.002368056,0.008555431,0.04689615,0.001444848,0.002365719,0.0006432077,0.0009890577,0.003514511,0.01444945,0.9184752,0.00008287844],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001955674,0.9933809,0.0006806754,0.002532319,0.0001336236,0.00003219138,0.0001535596,0.00001653287,0.00111445],"genre_scores_gemma":[0.008757355,0.986555,0.002103319,0.001496824,0.0004947681,0.00007211637,0.0002172789,0.000009337275,0.0002939948],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005798019,"threshold_uncertainty_score":0.03066325,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02203002502274497,"score_gpt":0.4331020654722201,"score_spread":0.4110720404494751,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}